Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Cardiol Therapeutics Inc.

    NASDAQ: CRDL · Real-Time Price · USD
    1.07
    -0.08 (-6.96%)
    At close: May 06, 2025, 3:59 PM
    1.05
    -1.77%
    After-hours: May 06, 2025, 05:15 PM EDT
    -6.96%
    Bid 1.02
    Market Cap 88.41M
    Revenue (ttm) n/a
    Net Income (ttm) -36.68M
    EPS (ttm) -0.36
    PE Ratio (ttm) -2.97
    Forward PE -2.92
    Analyst Buy
    Ask 1.21
    Volume 189,097
    Avg. Volume (20D) 227,188
    Open 1.11
    Previous Close 1.15
    Day's Range 1.05 - 1.15
    52-Week Range 0.77 - 3.12
    Beta 0.66

    About CRDL

    Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respirat...

    [Read more]
    Industry Drug Manufacturers - Specialty & Generic
    Sector Healthcare
    IPO Date Jan 15, 2019
    Employees 18
    Stock Exchange NASDAQ
    Ticker Symbol CRDL
    Website https://www.cardiolrx.com
    Full Company Profile

    Analyst Forecast

    According to 3 analyst ratings, the average rating for CRDL stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 741.12% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    7 months ago
    -6.63%
    Cardiol Therapeutics shares are trading lower afte... Unlock content with Pro Subscription
    6 months ago
    +3.7%
    Cardiol Therapeutics shares are trading lower after the company announced a preliminary prospectus for a proposed public offering of common stock, size or amount not disclosed.
    news image

    1 week ago · newsfilecorp.com

    Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors

    Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experience Toronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: C...

    news image

    2 weeks ago · zacks.com

    Cardiol Therapeutics Stock: Is Cannabis Potential Priced In?

    Cardiol Therapeutics shows promise with its CBD-based heart therapy, but a lack of approved drugs and a narrow pipeline raise red flags for cautious investors.

    news image

    2 weeks ago · newsfilecorp.com

    Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

    Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago. Based on a successful end-of-...

    news image

    1 month ago · newsfilecorp.com

    Cardiol Therapeutics Announces Year-End 2024 Update on Operations

    Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the P...

    news image

    2 months ago · newsfilecorp.com

    Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

    Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing ant...

    news image

    2 months ago · newsfilecorp.com

    Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure

    Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death - key underlying mechanisms in heart failure Toronto, Ontario--(Newsfi...

    Add to Watchlist